Potentiator Ivacaftor Abrogates Pharmacological Correction of ΔF508 CFTR in Cystic Fibrosis

Cystic Fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR). Newly developed “correctors” such as lumacaftor (VX-809) that improve CFTR maturation and trafficking and “potentiators” such as ivacaftor (VX-770) that enhance channel activity may provide important ad...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Sci Transl Med
Päätekijät: Cholon, Deborah M., Quinney, Nancy L., Fulcher, M. Leslie, Esther, Charles R., Das, Jhuma, Dokholyan, Nikolay V., Randell, Scott H., Boucher, Richard C., Gentzsch, Martina
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4272825/
https://ncbi.nlm.nih.gov/pubmed/25101886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3008680
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia